GREENFIELD, Ind. / Sep 05, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023 and Tuesday, September 12, 2023. Jeff Simmons, president and CEO, will participate in a fireside chat on Monday at 4:15 p.m. ET.
A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose– all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com
| Last Trade: | US$13.02 |
| Daily Change: | 0.20 1.56 |
| Daily Volume: | 7,750,767 |
| Market Cap: | US$6.440B |
February 25, 2025 February 25, 2025 November 15, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
